Literature DB >> 12090422

Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma.

Michael Frost1, Elke A Jarboe, David Orlicky, Roberto Gianani, L Chesney Thompson, Takayuki Enomoto, Kenneth R Shroyer.   

Abstract

Survivin is an inhibitor of apoptosis protein (IAP) that is expressed in fetal development and in cancer Survivin expression in premalignant lesions remains undefined. We obtained 73 samples of cervical squamous tissue, including 31 normal, 17 low- and 15 high-grade squamous intraepithelial lesions (LSILs, HSILs), and 10 squamous cell carcinomas (SCCs)from cone biopsy and hysterectomy specimens, and stained for survivin using an immunoperoxidase method. Nuclear staining was detected in normal mucosa, LSILs, and HSILs; staining intensity was greatest in cases with morphologic evidence of human papillomavirus (HPV) infection. In situ hybridization of serial sections demonstrated colocalization of HPV DNA and survivin. Cytoplasmic staining was observed in immature squamous metaplasia and in SCCs. Survivin expression in immature metaplastic squamous mucosa may reflect a rolefor survivin in normal squamous differentiation. However, the histologic correlation between nuclear staining and HPV infection suggests involvement of survivin in HPV-mediated disruption of normal cellular maturation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12090422     DOI: 10.1309/6V09-38K3-JQ40-UR50

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

Review 1.  Survivin and leukemia.

Authors:  Xiu Li Cong; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

2.  Relationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region.

Authors:  Manal M Zyada
Journal:  Med Oncol       Date:  2010-06-04       Impact factor: 3.064

Review 3.  Nuclear or cytoplasmic expression of survivin: what is the significance?

Authors:  Fengzhi Li; Jie Yang; Nithya Ramnath; Milind M Javle; Dongfeng Tan
Journal:  Int J Cancer       Date:  2005-04-20       Impact factor: 7.396

4.  Survivin expression in pre-invasive lesions and non-small cell lung carcinoma.

Authors:  Nalan Akyürek; Leyla Memiş; Ozgür Ekinci; Nurdan Köktürk; Can Oztürk
Journal:  Virchows Arch       Date:  2006-06-30       Impact factor: 4.064

5.  Clinicopathological significance of survivin expression in patients with cervical cancer: A systematic meta-analysis.

Authors:  Yibing Fan; Juan Chen
Journal:  Bioengineered       Date:  2017-01-04       Impact factor: 3.269

6.  Survivin promoter polymorphism and cervical carcinogenesis.

Authors:  A A Borbély; M Murvai; K Szarka; J Kónya; L Gergely; Z Hernádi; G Veress
Journal:  J Clin Pathol       Date:  2006-05-19       Impact factor: 3.411

7.  Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of tumor suppressor p16(INK4a) protein and confers resistance to oxidative stress.

Authors:  Chin-Yi Kan; Carlotta Petti; Lauryn Bracken; Michelle Maritz; Ning Xu; Rosemary O'Brien; Chen Yang; Tao Liu; Jun Yuan; Richard B Lock; Karen L MacKenzie
Journal:  J Biol Chem       Date:  2013-02-28       Impact factor: 5.157

8.  Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival.

Authors:  Antonio Martinez; Beatriz Bellosillo; Francesc Bosch; Ana Ferrer; Silvia Marcé; Neus Villamor; German Ott; Emili Montserrat; Elias Campo; Dolors Colomer
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

Review 9.  Current developments in adenovirus-based cancer gene therapy.

Authors:  Daniel T Rein; M Breidenbach; David T Curiel
Journal:  Future Oncol       Date:  2006-02       Impact factor: 3.404

10.  Survivin expression in oral squamous cell carcinoma.

Authors:  L Lo Muzio; G Pannone; S Staibano; M D Mignogna; C Rubini; M A Mariggiò; M Procaccini; F Ferrari; G De Rosa; D C Altieri
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.